Compare Novavax Inc (NVAX) vs Weyerhaeuser Company Common Stock (WY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Weyerhaeuser Company Common Stock — how do they compare? Novavax Inc trades at $12.35 (market cap $2.08B), while Weyerhaeuser Company Common Stock trades at $19.15 (market cap $13.62B). The key difference: Weyerhaeuser Company Common Stock is far larger — about 6.5× Novavax Inc's market cap, and Weyerhaeuser Company Common Stock pays a 4.44% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | WY | |
|---|---|---|
Market Cap | $2.08B | $13.62B |
Volume | 8,501,139 | 8,637,043 |
Sector | Health | Real Estate |
52-Week High | $12.82 | $27.10 |
52-Week Low | $6.22 | $18.47 |
Typical Hold Time | 59 Days | — |
Enterprise Value | $1.66B | $18.54B |
Dividend Yield | — | 4.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.82, up 1.26% with a bullish technical outlook. The company reported strong revenue of $1.12B in 2025 and net income of $440.30M, marking a significant turnaround. Recent earnings beats and FDA approvals for updated COVID-19 vaccines support momentum. However, negative cash flow and high debt levels pose challenges.
The outlook is mixed: analyst consensus is 74% Buy with bullish technical signals, but profitability remains volatile. Key risks include cash burn and competitive pressure. Upside depends on successful Matrix-M platform adoption and partnership execution. Investors should weigh strong recent performance against fundamental weaknesses.
Weyerhaeuser (WY) trades at $18.97, up 0.16% with neutral technical signals. The stock shows strong earnings momentum, beating estimates for three consecutive quarters, while fundamentals reveal modest profitability with 6.89% net margin and 4.97% ROE. Recent news highlights institutional accumulation and upcoming Q3 earnings on October 29. The company maintains stable revenue at $6.9B but faces cash flow challenges with negative net cash flow of $203M in 2025.
Weyerhaeuser presents a mixed outlook with analyst consensus favoring bullish sentiment (52% buy ratings) and a $29.33 price target suggesting 55% upside. However, risks include weak dividend coverage, high leverage at 5x, and sensitivity to interest rates and housing market cycles. The stock's current proximity to 52-week lows offers potential value but requires careful monitoring of lumber demand recovery and Q3 earnings results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Weyerhaeuser Company Common Stock
Weyerhaeuser Company is a timberland-focused real estate investment trust (REIT) that owns and manages more than 10 million acres of timberland in US, in addition to timberlands under long-term license in Canada. The company also manufactures wood products, including lumber, oriented strand board, and engineered wood.
Read more on WY →
